Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company.